In this regard, it has been described that cisplatinum-resistant ovarian cancer cells acquire platinum resistance through the activation of an adaptive ETAR/β-arr1/YAP/TAZ signaling cascade that sustains cell survival, cell plasticity, and lowers cisplatinum sensitivity. The gene discussed is EDNRA; the disease is ovarian cancer.